Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis

Clara Matute-Blanch, Jordi Río, Luisa M. Villar, Luciana Midaglia, Sunny Malhotra, José C. Álvarez-Cermeño, Angela Vidal-Jordana, Xavier Montalban, Manuel Comabella

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

© 2016 Elsevier B.V. Chitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFNβ) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFNβ-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p = 0.014) but unchanged by IFNβ (p = 0.830). CHI3L1 was associated with IFNβ response and levels were higher in non-responder group (p = 0.020), while GA showed no responder effect (p = 0.943). These results suggest a role for CHI3L1 as response biomarker to IFNβ in RRMS patients.
Original languageEnglish
Pages (from-to)62-65
JournalJournal of Neuroimmunology
Volume303
DOIs
Publication statusPublished - 15 Feb 2017

Keywords

  • Biomarkers
  • Chitinase 3-like 1
  • Glatiramer acetate
  • Interferon-beta
  • Multiple sclerosis

Fingerprint Dive into the research topics of 'Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Matute-Blanch, C., Río, J., Villar, L. M., Midaglia, L., Malhotra, S., Álvarez-Cermeño, J. C., Vidal-Jordana, A., Montalban, X., & Comabella, M. (2017). Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. Journal of Neuroimmunology, 303, 62-65. https://doi.org/10.1016/j.jneuroim.2016.12.006